BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Samaritan Pharmaceuticals, Inc. (SPHC) In-Licenses Rights To Promote And Sell Six Of Molteni's Prescription Drugs For Pain, Drug Addiction And Anesthesia In Greece And Cyprus


1/16/2007 12:33:35 PM

LAS VEGAS, Jan. 16, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV - News), a developer of innovative drugs, is pleased to announce that it has signed an exclusive license with Molteni Farmaceutici, Italy in-licensing the marketing and sales rights for six prescription medications: Oramorph(tm), Morphine Sulphate, Methadone, Naloxone Molteni(tm), Naltrexone(tm), and Mepivamol(tm), in Greece and Cyprus. ``Samaritan commends Mr. Eugene Boyle and Dr. Christos Dakas for their resiliency in exacting Samaritan's in-licensing revenue strategy. Samaritan has advanced its first in-licensed drug Amphocil's registration in Greece and expects sales revenue in 2007. Samaritan believes its expertise in registration, marketing and sales and distribution in overlooked territories such as Eastern Europe will allow Samaritan to continually increase its in-licensing portfolio of prescription drugs.'' said Dr. Janet Greeson, CEO of Samaritan.

Samaritan will distribute Molteni products through hospitals. Samaritan plans to submit the products under this agreement to the Greece and Cypress governmental market authorization authorities for Greece and Cypress regulatory approval, as soon as Molteni transfers the stated drugs' regulatory package.

http://www.samaritanpharma.com/marketed_products.asp

PAIN RELIEF MEDICATIONS

About Oramorph(tm)

Oramorph(tm) is morphine sulphate in an oral solution and is used for managing moderate to severe chronic pain.

About Morphine Sulphate (Injectable Formulation)

Morphine Sulphate relieves moderate to severe pain by binding to brain receptors. Morphine Sulphate may be used to control the pain following surgery, child birth, and other procedures. It may also be used to treat the pain associated with cancer, heart attacks, sickle cell disease and other medical conditions.

DRUG ADDICTION THERAPY

About Methadone

Methadone is an opiate agonist. Methadone prevents heroin or morphine from interacting with receptors for natural painkillers called endorphins, blocking the effects of the addictive drugs and reducing the physical cravings.

About Naloxone Molteni(tm)

Naloxone Molteni(tm) is an opioid antagonist which reverses the effects of opioid overdose, for example heroin and morphine overdose. Specifically, Naloxone(tm) is used in opioid overdoses for countering life-threatening depression of the central nervous system and respiratory system.

About Naltrexone(tm)

Naltrexone(tm) is an opioid antagonist which is used to help people who have a narcotic or alcohol addiction stay drug free. Naltrexone(tm) is used after the patient has stopped taking drugs or alcohol. It works by blocking the effects of narcotics or by decreasing the craving for alcohol.

ANESTHESIA MEDICATION

About Mepivamol(tm) (Mepivacaine)

Mepivamol(tm) is an effective and reliable local anesthetic of intermediate duration and low systemic toxicity. It is widely used for regional anesthetic procedures such as IVRA, infiltration, epidural blockade, plexus and peripheral nerve blockade.

About Molteni Farmaceutici

Molteni is rich in history with over a century of experience beginning with the opening of its manufacturing facility at the Molteni Pharmacy Laboratory located in the historic center of Florence, Italy. The strategic therapeutic areas on which Molteni makes an effort for trading new alliances are concentrated on Analgesia, Anesthesia and Drug Addition Therapy.

About Samaritan

Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at http://www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.

The Samaritan Pharmaceuticals Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670

Samaritan Pharmaceuticals: ``We LIV... to Save Lives.''

Disclaimer

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K/A filed November 2, 2006. The company undertakes no duty to update forward-looking statements.

Contact: Samaritan Pharmaceuticals, Inc. Richard Brown (702) 735-7001 rbrown@SamaritanPharma.com www.SamaritanPharma.com

Source: Samaritan Pharmaceuticals, Inc.

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES